SG11201806982PA - Cinnolin-4-amine compounds and their use in treating cancer - Google Patents

Cinnolin-4-amine compounds and their use in treating cancer

Info

Publication number
SG11201806982PA
SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA
Authority
SG
Singapore
Prior art keywords
compounds
salts
international
astrazeneca
pct
Prior art date
Application number
SG11201806982PA
Other languages
English (en)
Inventor
Kurt Pike
Bernard Barlaam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201806982PA publication Critical patent/SG11201806982PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
SG11201806982PA 2016-03-21 2017-03-20 Cinnolin-4-amine compounds and their use in treating cancer SG11201806982PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662310883P 2016-03-21 2016-03-21
PCT/EP2017/056592 WO2017162605A1 (fr) 2016-03-21 2017-03-20 Composés cinnolin-4-amine et leur utilisation pour traiter le cancer

Publications (1)

Publication Number Publication Date
SG11201806982PA true SG11201806982PA (en) 2018-09-27

Family

ID=58361025

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806982PA SG11201806982PA (en) 2016-03-21 2017-03-20 Cinnolin-4-amine compounds and their use in treating cancer

Country Status (18)

Country Link
US (1) US20190099421A1 (fr)
EP (1) EP3433251A1 (fr)
JP (1) JP2019512512A (fr)
KR (1) KR20180127419A (fr)
CN (1) CN108884084A (fr)
AR (1) AR107937A1 (fr)
AU (1) AU2017237394A1 (fr)
BR (1) BR112018068347A2 (fr)
CA (1) CA3017035A1 (fr)
CO (1) CO2018010951A2 (fr)
DO (1) DOP2018000197A (fr)
IL (1) IL261648A (fr)
MA (1) MA43733A (fr)
MX (1) MX2018011283A (fr)
PE (1) PE20181895A1 (fr)
SG (1) SG11201806982PA (fr)
TW (1) TW201808939A (fr)
WO (1) WO2017162605A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019057757A1 (fr) * 2017-09-20 2019-03-28 Astrazeneca Ab Composés 1,3-dihydroimidazo[4,5-c]cinnolin-2-one et leur utilisation dans le traitement du cancer
US20210353614A1 (en) * 2018-03-14 2021-11-18 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
EP3849984A4 (fr) 2018-09-14 2022-06-01 Suzhou Zanrong Pharma Limited 1-isopropyl-3-méthyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one servant de modulateurs sélectifs de la kinase ataxie télangiectasie (atm) mutée et utilisations associées
WO2021260580A1 (fr) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de l'atm

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
EP2668162A1 (fr) 2011-01-28 2013-12-04 Novartis AG Composés bi-hétéroaryles substitués en tant qu'inhibiteurs de cdk9 et leurs utilisations
EP2726465A1 (fr) * 2011-05-23 2014-05-07 Elan Pharmaceuticals Inc. Inhibiteurs de l'activité lrrk2 kinase
NO2714752T3 (fr) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
US20190099421A1 (en) 2019-04-04
MA43733A (fr) 2018-11-28
TW201808939A (zh) 2018-03-16
EP3433251A1 (fr) 2019-01-30
WO2017162605A1 (fr) 2017-09-28
PE20181895A1 (es) 2018-12-11
AU2017237394A1 (en) 2018-11-01
CA3017035A1 (fr) 2017-09-28
MX2018011283A (es) 2019-05-27
AR107937A1 (es) 2018-06-28
KR20180127419A (ko) 2018-11-28
CN108884084A (zh) 2018-11-23
BR112018068347A2 (pt) 2019-01-15
IL261648A (en) 2018-10-31
CO2018010951A2 (es) 2018-10-22
JP2019512512A (ja) 2019-05-16
DOP2018000197A (es) 2018-10-15

Similar Documents

Publication Publication Date Title
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201903182XA (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201908065YA (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201804587QA (en) Isoindole compounds
SG11201906222WA (en) Jak1 selective inhibitors
SG11201806982PA (en) Cinnolin-4-amine compounds and their use in treating cancer
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201906767XA (en) Estrogen receptor modulators
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201408509PA (en) Racecadotril lipid compositions
SG11201806424TA (en) Therapeutic compounds
SG11201810940XA (en) Methods of treating pancreatic cancer